Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Cell Death Dis ; 15(6): 440, 2024 Jun 22.
Article in English | MEDLINE | ID: mdl-38909035

ABSTRACT

The transmembrane death receptor Fas transduces apoptotic signals upon binding its ligand, FasL. Although Fas is highly expressed in cancer cells, insufficient cell surface Fas expression desensitizes cancer cells to Fas-induced apoptosis. Here, we show that the increase in Fas microaggregate formation on the plasma membrane in response to the inhibition of endocytosis sensitizes cancer cells to Fas-induced apoptosis. We used a clinically accessible Rho-kinase inhibitor, fasudil, that reduces endocytosis dynamics by increasing plasma membrane tension. In combination with exogenous soluble FasL (sFasL), fasudil promoted cancer cell apoptosis, but this collaborative effect was substantially weaker in nonmalignant cells. The combination of sFasL and fasudil prevented glioblastoma cell growth in embryonic stem cell-derived brain organoids and induced tumor regression in a xenograft mouse model. Our results demonstrate that sFasL has strong potential for apoptosis-directed cancer therapy when Fas microaggregate formation is augmented by mechano-inhibition of endocytosis.


Subject(s)
Apoptosis , Endocytosis , Fas Ligand Protein , fas Receptor , Humans , Endocytosis/drug effects , Apoptosis/drug effects , Animals , Fas Ligand Protein/metabolism , fas Receptor/metabolism , Mice , Cell Line, Tumor , 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine/analogs & derivatives , 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine/pharmacology , Xenograft Model Antitumor Assays , Glioblastoma/pathology , Glioblastoma/metabolism , Glioblastoma/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL